Adenosine nucleobase editors and uses thereof
US-10113163-B2 · Oct 30, 2018 · US
Elimination of colonic bacterial driving lethal inflammatory cardiomyopathy
US11617773B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11617773-B2 |
| Application number | US-202117225854-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 8, 2021 |
| Priority date | Apr 8, 2020 |
| Publication date | Apr 4, 2023 |
| Grant date | Apr 4, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to methods, kits and compositions for reducing the level of or eliminating Bacteroides in situ. The invention encompasses methods of preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof, comprising reducing the amount of Bacteroides sp. in the subject. The invention further encompasses methods of diagnosis of a subject as having myocarditis or dilated cardiomyopathy. The invention also encompasses compositions preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof.
First claim
Opening claim text (preview).
We claim: 1. A method of limiting progression of myocarditis toward dilated cardiomyopathy (DCM) in a subject in need thereof, comprising reducing the amount of B. thetaiotaomicron and/or B. faecis in the subject by orally or enterally administering to the subject an effective amount of a recombinant phage or packaged phagemid that targets the B. thetaiotaomicron and/or B. faecis and encodes a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas nuclease and a guide RNA that are designed to specifically cleave the genome of the B. thetaiotaomicron and/or B. faecis to reduce the amount of the B. thetaiotaomicron and/or B. faecis in the intestine of the subject. 2. The method of claim 1 , wherein the CRISPR-Cas nuclease is Cas9. 3. The method of claim 1 , wherein the CRISPR-Cas nuclease is Cpf1 (Cas12a). 4. The method of claim 1 , wherein the CRISPR-Cas nuclease is Cas 3. 5. The method of claim 1 , wherein the recombinant phage or packaged phagemid is enterally administered to the subject. 6. The method of claim 1 , wherein the recombinant phage or packaged phagemid is orally administered to the subject. 7. The method of claim 1 , wherein the recombinant phage or packaged phagemid targets the B. thetaiotaomicron.
Assignees
Inventors
Classifications
having a heterocyclic ring, e.g. sulfadiazine · CPC title
Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin} · CPC title
Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title
involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title
containing five-membered rings with nitrogen as a ring hetero atom · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11617773B2 cover?
- The invention relates to methods, kits and compositions for reducing the level of or eliminating Bacteroides in situ. The invention encompasses methods of preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof, comprising reducing the amount of Bacteroides sp. in the subject. The i…
- Who is the assignee on this patent?
- Eligo Bioscience, St Gallen Kantonsspital
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4164. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).